Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Evidence of Endothelial Dysfunction and Activation of RhoA/Rho Kinase Pathway in Inflammatory Bowel Disease

Jaime Pereira, MD, Claudia G Saez, PhD, Manuel Alvarez, MD, Felipe Silva, MD, Nixa Olivares, Jose G Valenzuela, Antonia Pastore, Diego Mezzano, MD

Blood (2019) 134 (Supplement_1): 3641.

https://doi.org/10.1182/blood-2019-126033

Published: 2019

Journal Articles

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Emilie Saucier, Florence Rabian, MD, Hélène Boutroux, MD, Marion Strullu, MD, Karine Morand, MD, Florian Chevillon, MD, Benoit Brethon, MD, Nicolas Boissel, MD PhD, Guy Leverger, MD, André Baruchel, MD

Blood (2019) 134 (Supplement_1): 5130.

https://doi.org/10.1182/blood-2019-131062

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy

Qayyim Said, PhD, Lincy S Lal, PhD, Katherine Andrade, Brigette Nezami, PharmD, J. Anthony Graves, MD, PhD, Anuja Roy, PhD, Adam Cuker, MD MS

Blood (2018) 132 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2018-99-111975

Published: 2018

Journal Articles

Inflammatory Bowel Disease and Hodgkin's Lymphoma: Two New Observations

Zoubida Tazi Mezalek, MD, Myriam Bourkia, Sofia Habib Allah, Noha Al Waragli, Majdouline Bouaouad, Amina Lhoussni, MD, Hajar Khibri, Wafaa Ammouri, Mouna Maamar, Hicham Harmouche, Mohammed Adnaoui

Blood (2018) 132 (Supplement 1): 5353.

https://doi.org/10.1182/blood-2018-99-110615

Published: 2018

Journal Articles

Ten New Cases of Hermansky-Pudlak Syndrome in the Iberian Peninsula: Identification of Novel Genetic Variants in HPS3, HPS4, HPS6 and DTNBP1 Associated with Significant Clinical Complications

Blood (2018) 132 (Supplement 1): 1147.

https://doi.org/10.1182/blood-2018-99-112968

Published: 2018

Journal Articles

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, MD, Haesook T Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Caron Jacobson, MD, Samuel Y. Ng, MDPhD, Ann S LaCasce, MD MSc, Ephraim P. Hochberg, MD, Ronald W. Takvorian, MD, Jeremy S. Abramson, MD MMSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 496.

https://doi.org/10.1182/blood.V130.Suppl_1.496.496

Published: 2017

Journal Articles

Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature

Terrence J Bradley, MD, Matthew P Salzberg, MD, George Nahas, DO, Basem Azab, MD, Alan Livingstone, MD, John J. Byrnes, MD, Thomas J. Harrington, MD, James E. Hoffman, MD

Blood (2017) 130 (Supplement 1): 4885.

https://doi.org/10.1182/blood.V130.Suppl_1.4885.4885

Published: 2017

Journal Articles

Anticoagulation Therapy Considerations in Left Ventricular Assist Devices in the Setting of Factor VII Deficiency

Anuhya Kommalapati, MD, Sri Harsha Tella, MD, Allan-Louie Cruz, MD

Blood (2017) 130 (Supplement 1): 4898.

https://doi.org/10.1182/blood.V130.Suppl_1.4898.4898

Published: 2017

Journal Articles

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert W Chen, MD, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, M. Lia Palomba, MD

Blood (2016) 128 (22): 1804.

https://doi.org/10.1182/blood.V128.22.1804.1804

Published: 2016

Journal Articles

Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy

Blood (2016) 128 (22): 3166.

https://doi.org/10.1182/blood.V128.22.3166.3166

Published: 2016

Journal Articles

Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Daniel Kobrinski, DO, Tulio E. Rodriguez, MD, Scott E. Smith, MD PhD, Stephanie B. Tsai, MD MA, Zeina Al-Mansour, MD, Mala Parthasarathy, MS, Patrick J. Stiff, MD

Blood (2016) 128 (22): 5795.

https://doi.org/10.1182/blood.V128.22.5795.5795

Published: 2016

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

Journal Articles

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H. Park, MD, B. Douglas Smith, MD, Moshe Yair Levy, MD, Elihu H. Estey, MD, Alexander E. Perl, MD, Hagop Kantarjian, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 3794.

https://doi.org/10.1182/blood.V126.23.3794.3794

Published: 2015

Journal Articles

Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report

Blood (2015) 126 (23): 3154.

https://doi.org/10.1182/blood.V126.23.3154.3154

Published: 2015

Journal Articles

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Results of Fol-Brite

Frederick Lansigan, MD, Bassem I Zaki, MD, Stephanie P Yen, MD, Eric S Winer, MD, Helen Ryan, MD, Darcie L Findley, Sara R Metzler, RN, Lynn Shaw, RN, Annie Tsui, RN, Todd MacKenzie, PhD, Anne W Beaven, MD

Blood (2014) 124 (21): 1733.

https://doi.org/10.1182/blood.V124.21.1733.1733

Published: 2014

Journal Articles

Long-Term Outcomes Of a Small Cohort At a Single Canadian Centre Of Severe Subunit A FXIII Deficient Patients (F13A1: c.691-1G>A) Treated Prophylactically With Fibrogammin P

Andrew P Sullivan, Jill MacDonald, Charlotte Sheppard, Mary-Frances Scully, MRCP, FRCP

Blood (2013) 122 (21): 2360.

https://doi.org/10.1182/blood.V122.21.2360.2360

Published: 2013

Journal Articles

Perioperative Management Of Patients On Dabigatran – a Prospective Cohort Study

Sam Schulman, MD, PhD, James Douketis, Rebecca Barty, MLT, BA, MSc(c), Agnes Y.Y. Lee, MD, MSc, FRCPC, Marc Carrier, MD, MSc, Fred Spencer, M.D., Mark D. Blostein, M.D., Susan Solymoss, MD, Sudeep Shivakumar, MD, BSc, Grace Wang, MMath, Nancy Heddle, MSc

Blood (2013) 122 (21): 3637.

https://doi.org/10.1182/blood.V122.21.3637.3637

Published: 2013

Journal Articles

Severe Acquired Bleeding Tendency Secondary To An Anti-Thrombin Antibody In a Patient With Monoclonal Gammapathy Of Unknown Significance: Direct In Vivo evidence

Valerie Proulle, MD, PhD, Celine Desconclois, PD, Cecile Lavenu-Bombled, MD, PhD, Cecile Goujard, MD, PhD, Anish V Sharda, MBBS, MPH, Ali G Turhan, MD, PhD

Blood (2013) 122 (21): 1111.

https://doi.org/10.1182/blood.V122.21.1111.1111

Published: 2013

Journal Articles

The Safety and Adherence To Prophylactic Anticoagulation During Induction Chemotherapy In Adults With Acute Lymphoblastic Leukemia

Rachael F. Grace, MD, Kristen E. Stevenson, MS, Donna S. Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD, Daniel J. DeAngelo, MD, Ph.D, Jean M. Connors, MD

Blood (2013) 122 (21): 3867.

https://doi.org/10.1182/blood.V122.21.3867.3867

Published: 2013

NARROW

Evidence of Endothelial Dysfunction and Activation of RhoA/Rho Kinase Pathway in Inflammatory Bowel Disease

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy

Inflammatory Bowel Disease and Hodgkin's Lymphoma: Two New Observations

Ten New Cases of Hermansky-Pudlak Syndrome in the Iberian Peninsula: Identification of Novel Genetic Variants in HPS3, HPS4, HPS6 and DTNBP1 Associated with Significant Clinical Complications

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature

Anticoagulation Therapy Considerations in Left Ventricular Assist Devices in the Setting of Factor VII Deficiency

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy

Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Results of Fol-Brite

Long-Term Outcomes Of a Small Cohort At a Single Canadian Centre Of Severe Subunit A FXIII Deficient Patients (F13A1: c.691-1G>A) Treated Prophylactically With Fibrogammin P

Perioperative Management Of Patients On Dabigatran – a Prospective Cohort Study

Severe Acquired Bleeding Tendency Secondary To An Anti-Thrombin Antibody In a Patient With Monoclonal Gammapathy Of Unknown Significance: Direct In Vivo evidence

The Safety and Adherence To Prophylactic Anticoagulation During Induction Chemotherapy In Adults With Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only